DEA and FDA Issue Joint Letter to the Public on Actions to Address Shortages in Prescription Stimulants

Update on the Prescription Stimulant Shortage (dea.gov)

Diversion Control Division | Stimulants (usdoj.gov)

Diversion Control Division | Quotas - 2023 Aggregate Production Quota for Methylphenidate (usdoj.gov)

DEA_Letter_to_Manufacturers.pdf (usdoj.gov)

May 7, 2024 - Statement of Administrator Anne Milgram - Fiscal Year 2025 Request for the Drug Enforcement Administration

April 30, 2024 - Statement of William F. Kimbell Chief of Operations Drug Enforcement Administration - Hearing Entitled, “TBD”

March 20, 2024 - Testimony of James Dunlap Deputy Under Secretary for Analysis Office of Intelligence and Analysis U.S. Department of Homeland Security - Examining the Current Status of Iran’s Axis of Resistance and the Implications for Homeland Security and U.S. Interests

October 24, 2023 - Statement of William F. Kimbell Chief of Operations Drug Enforcement Administration - Hearing Entitled, “TBD”

July 27, 2023 - Statement of Administrator Anne Milgram - Drug Enforcement Administration Oversight

July 12, 2023 - Statement of Kemp L. Chester Senior Advisor, Office of National Drug Control Policy Committee on Homeland Security - Leading the Strategic Response to Disrupt the Flow of Illicit Fentanyl Across Our Borders

June 21, 2023 - Statement of Matthew J. Strait Deputy Assistant Administrator Diversion Control Division - Responding to America's Overdose Crisis: An Examination of Legislation to Build Upon the SUPPORT Act

May 10, 2023 - Statement of Administrator Anne Milgram - A Review of the President’s Fiscal Year 2024 Funding Requests for the Federal Bureau of Investigation and for the U.S. Drug Enforcement Administration

April 27, 2023 - Statement of Administrator Anne Milgram - Fiscal Year 2024 Request for the Drug Enforcement Administration

February 15, 2023 - Statement of Administrator Anne Milgram - Countering Illicit Fentanyl Trafficking

February 1, 2023 - Statement of Associate Administrator Jon DeLena - Lives Worth Living: Addressing the Fentanyl Crisis, Protecting Critical Lifelines, and Combatting Discrimination Against Those with Disabilities 

National Drug Threat Assessment 2024
The Growing Threat of Xylazine and its Mixture with Illicit Drugs (dea.gov)

DEA FY 2025 Narrative

2024 | 2023 | 2022 | 2021